--- title: "Vutrisiran (Amvuttra): The First RNAi Drug Proven to Cut Cardiovascular Death - How Alnylam's Quarterly TTR-Silencing Injection Treats ATTR Amyloidosis and What HELIOS-B Showed (August 19, 2026) | PepTracker Pro Blog" url: https://peptrackerpro.com/blog/vutrisiran-amvuttra-alnylam-ttr-transthyretin-galnac-sirna-rnai-attr-amyloidosis-cardiomyopathy-attr-cm-helios-a-helios-b-cardiovascular-outcomes-quarterly-august-19-2026 description: "Most gene-silencing drugs move a lab value. Vutrisiran moved mortality. Alnylam's quarterly subcutaneous injection silences the TTR gene in the liver to treat ATTR amyloidosis, and in the HELIOS-B trial it became the first RNAi therapeutic proven to reduce cardiovascular death and events in ATTR cardiomyopathy. Here is how it works, from GalNAc chemistry to the heart data that earned its 2025 label." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) Research & Compounds Research & Compounds # Vutrisiran (Amvuttra): The First RNAi Drug Proven to Cut Cardiovascular Death - How Alnylam's Quarterly TTR-Silencing Injection Treats ATTR Amyloidosis and What HELIOS-B Showed (August 19, 2026) PepTracker Pro Research Team August 19, 2026 8 min read ## Table of Contents - The first RNAi drug to move a cardiovascular needle - The disease: a protein that turns to concrete - The idea: stop making the protein - The delivery trick: a sugar tag for the liver - From an IV infusion to a quarterly shot - HELIOS-A: proving it in the nerves - HELIOS-B: proving it in the heart - Why 'first RNAi to reduce cardiovascular events' is a big deal - How to think about it next to the stabilizers - The bottom line and the cautions ## The first RNAi drug to move a cardiovascular needle For most of its history, RNA interference was a laboratory phenomenon and then, at best, a treatment for rare inherited diseases. Vutrisiran - sold as Amvuttra by Alnylam - is the drug that changed the stakes. In March 2025 the U.S. FDA expanded its label to transthyretin amyloid cardiomyopathy (ATTR-CM), making it the first RNAi therapeutic ever shown to reduce cardiovascular death and cardiovascular events. That is a milestone not just for one disease but for an entire drug class: the same liver-targeted 'gene-silencing' technology behind the cholesterol medicine inclisiran and a wave of investigational cardiometabolic siRNAs. Here is what vutrisiran is, how it works, and what the trials actually showed. ## The disease: a protein that turns to concrete Transthyretin, or TTR, is a protein your liver makes to ferry thyroid hormone and vitamin A around the bloodstream. In transthyretin amyloidosis (ATTR), TTR molecules become unstable - either because of an inherited mutation (hereditary ATTR) or simply through ageing of the normal protein (wild-type ATTR) - and misfold into sticky amyloid fibrils. Those fibrils deposit where they are hardest to remove: in peripheral nerves, causing a painful, disabling polyneuropathy, and in the heart muscle, stiffening it into a form of heart failure called ATTR cardiomyopathy (ATTR-CM). Left untreated, ATTR-CM is progressive and fatal. For decades there was nothing to offer but symptom management. ## The idea: stop making the protein Older approaches to ATTR try to hold the TTR protein together after it is made - so-called stabilizers like tafamidis and acoramidis that clamp the TTR tetramer so it misfolds less. Vutrisiran attacks the problem one step earlier: it stops the liver from making so much TTR in the first place. It is a small interfering RNA (siRNA), a short piece of double-stranded RNA that plugs into the cell's natural RNA interference machinery and triggers the destruction of the messenger RNA that codes for TTR - both the mutant and the normal wild-type versions. Less messenger RNA means less TTR protein, which means less raw material for amyloid. In trials, vutrisiran knocks circulating TTR down by around 80 percent. ## The delivery trick: a sugar tag for the liver Getting an siRNA into the right cells is the hard part. Vutrisiran solves it with GalNAc - triantennary N-acetylgalactosamine, a sugar cluster bolted onto the RNA. GalNAc is recognized almost exclusively by a receptor on liver cells, so a simple injection under the skin funnels the drug straight to the hepatocytes where TTR is made. Combined with Alnylam's Enhanced Stabilization Chemistry, which makes the RNA rugged enough to last, one 25 mg subcutaneous shot silences TTR for a full three months. That is why vutrisiran is dosed just four times a year. It is the same GalNAc-siRNA platform that underlies inclisiran for cholesterol and the investigational siRNAs olpasiran, lepodisiran, zerlasiran, zilebesiran, zodasiran, solbinsiran and plozasiran. ## From an IV infusion to a quarterly shot Vutrisiran did not appear from nowhere. Its predecessor, patisiran (Onpattro), was the world's first approved siRNA drug (2018) and also silenced TTR - but it was delivered inside a lipid nanoparticle by intravenous infusion every three weeks, with steroids and antihistamines beforehand to blunt reactions. Vutrisiran is what happened when Alnylam swapped the lipid-nanoparticle IV for a GalNAc sugar tag and a syringe: same target, same disease-modifying idea, but a quarterly injection you could get in a clinic in minutes. That jump - infusion to quarterly shot - is the single clearest illustration of how chemistry turned RNAi from a hospital procedure into a practical chronic therapy. ## HELIOS-A: proving it in the nerves The first approval came from HELIOS-A, a Phase 3 trial in 164 adults with the polyneuropathy of hereditary ATTR. Patients got vutrisiran 25 mg every three months, and the study used the placebo group from the earlier patisiran trial as an external comparison. At 9 and 18 months, vutrisiran significantly improved a standardized measure of nerve impairment (mNIS+7) and quality of life, and a majority of patients saw their neuropathy halt or even reverse. Serum TTR dropped about 83 percent. On that basis the FDA approved Amvuttra for hATTR polyneuropathy in June 2022. ## HELIOS-B: proving it in the heart The landmark result came later. HELIOS-B (published in the New England Journal of Medicine in 2024) randomized 655 adults with ATTR cardiomyopathy to vutrisiran or placebo every three months for up to three years - and importantly, most patients were already taking the stabilizer tafamidis, so vutrisiran had to prove benefit on top of existing therapy. It did. The primary composite of death from any cause plus recurrent cardiovascular events was reduced with a hazard ratio of 0.72 (95% CI 0.56-0.93), a 28 percent relative reduction; in patients taking vutrisiran as monotherapy the hazard ratio was 0.67. All-cause mortality through 42 months fell with a hazard ratio of 0.65 - roughly a 36 percent reduction - and patients also walked farther and reported better quality of life. Those data drove the March 2025 FDA label expansion to ATTR-CM. ## Why 'first RNAi to reduce cardiovascular events' is a big deal Plenty of siRNA drugs lower a number - LDL cholesterol, lipoprotein(a), triglycerides. What HELIOS-B added was a hard clinical outcome: fewer deaths and fewer cardiovascular events, not just a better lab value. That is the endpoint regulators, cardiologists and payers care about most, and vutrisiran is the first RNA interference medicine to deliver it. It is an existence proof for the whole GalNAc-siRNA field that gene silencing can translate into lives extended - the very question the cardiovascular outcomes trials for inclisiran and the Lp(a) and triglyceride siRNAs are still working to answer in their own diseases. ## How to think about it next to the stabilizers ATTR-CM now has two strategies that can be complementary rather than competing. Stabilizers (tafamidis, acoramidis) hold the TTR tetramer together so it misfolds less; silencers (vutrisiran, and the investigational antisense drug eplontersen) reduce how much TTR is made at all. HELIOS-B specifically showed benefit when vutrisiran was added on top of a stabilizer background, which has fueled interest in silence-plus-stabilize combinations. The trade-offs are real - cost, the permanence of deep silencing, and the need for vitamin A supplementation since TTR carries vitamin A - but the direction of travel is toward attacking the amyloid from more than one angle. ## The bottom line and the cautions Vutrisiran is a genuine landmark: a quarterly, under-the-skin injection that treats a once-untreatable, fatal amyloid disease at its source, and the first RNAi drug proven to reduce cardiovascular death and events. It is an approved prescription biologic given by a healthcare professional - not a supplement, and anything sold online as 'vutrisiran' or 'Amvuttra' outside a pharmacy is unverified and unsafe. Its main practical wrinkles are injection-site reactions, the need for vitamin A supplementation, and the fact that it treats ATTR - not AL - amyloidosis, so the amyloid type must be confirmed first. This article is educational and not medical advice; decisions about ATTR treatment, including whether to silence, stabilize, or do both, belong with a specialist. Ready to track your peptide research? Open PepTracker Pro (https://app.peptrackerpro.com/) PepTracker Pro Research Team The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges. ## Citations 1. [1] Fontana M, Berk JL, Gillmore JD, et al. - Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (HELIOS-B), New England Journal of Medicine (2024) Source (https://www.nejm.org/doi/full/10.1056/NEJMoa2409134) 2. [2] Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death and Events in ATTR-CM (March 2025) Source (https://investors.alnylam.com/press-release?id=28831) 3. [3] Adams D, Tournev IL, Taylor MS, et al. - Efficacy and safety of vutrisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy (HELIOS-A), Amyloid (2022) Source (https://www.tandfonline.com/doi/full/10.1080/13506129.2022.2091985) 4. [4] HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy - ClinicalTrials.gov, NCT04153149 Source (https://clinicaltrials.gov/study/NCT04153149) 5. [5] Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran) for the Polyneuropathy of Hereditary ATTR Amyloidosis (June 13, 2022) Source (https://investors.alnylam.com/press-release?id=26776) 6. [6] AMVUTTRA (vutrisiran) injection - U.S. Prescribing Information (Alnylam) Source (https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215515s006lbl.pdf) **Disclaimer:** This article is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider. Read full research disclaimer → (https://peptrackerpro.com/research-disclaimer) ## Related Articles Research & Compounds cover image (https://peptrackerpro.com/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026) Research & Compounds ### Zilebesiran: The Twice-a-Year RNAi Shot That Silences Angiotensinogen to Lower Blood Pressure - KARDIA-1, KARDIA-2, KARDIA-3 and the Phase 3 ZENITH Outcomes Trial (August 14, 2026) (https://peptrackerpro.com/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026) Most blood-pressure drugs must be taken every day, and most patients never reach goal. Zilebesiran takes a different route: a GalNAc-siRNA injection given as rarely as twice a year that silences angiotensinogen - the single upstream protein behind the entire renin-angiotensin system - and lowers systolic blood pressure for up to 6 months from one dose. Here is what KARDIA-1, KARDIA-2 and KARDIA-3 showed, and what the 11,000-patient Phase 3 ZENITH outcomes trial is testing. PepTracker Pro Team August 14, 2026 8 min read Read (https://peptrackerpro.com/blog/zilebesiran-alnylam-roche-genentech-angiotensinogen-agt-galnac-sirna-rnai-hypertension-blood-pressure-raas-kardia-1-kardia-2-kardia-3-zenith-cardiovascular-outcomes-august-14-2026) Research & Compounds cover image (https://peptrackerpro.com/blog/inclisiran-leqvio-novartis-alnylam-pcsk9-galnac-sirna-rnai-ldl-cholesterol-twice-yearly-orion-9-orion-10-orion-11-victorion-2-prevent-cardiovascular-outcomes-monotherapy-august-17-2026) Research & Compounds ### Inclisiran (Leqvio): The Twice-a-Year siRNA Injection That Halves LDL Cholesterol - How PCSK9 Silencing Works and Where the Outcomes Data Stand (August 17, 2026) (https://peptrackerpro.com/blog/inclisiran-leqvio-novartis-alnylam-pcsk9-galnac-sirna-rnai-ldl-cholesterol-twice-yearly-orion-9-orion-10-orion-11-victorion-2-prevent-cardiovascular-outcomes-monotherapy-august-17-2026) Statins and daily pills lose their power when patients stop taking them. Inclisiran (Leqvio) takes a different route: a subcutaneous injection given just twice a year that silences the liver protein PCSK9 and cuts LDL cholesterol by about half. It was the first RNA-interference medicine approved for a common chronic cardiovascular condition, and in 2025 the FDA broadened its label to first-line use. Here is how PCSK9 silencing works, what the ORION trials showed, how inclisiran compares with the PCSK9 antibodies, and why the VICTORION outcomes trials are the test that still matters. PepTracker Pro Team August 17, 2026 8 min read Read (https://peptrackerpro.com/blog/inclisiran-leqvio-novartis-alnylam-pcsk9-galnac-sirna-rnai-ldl-cholesterol-twice-yearly-orion-9-orion-10-orion-11-victorion-2-prevent-cardiovascular-outcomes-monotherapy-august-17-2026) ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "Article", "headline": "Vutrisiran (Amvuttra): The First RNAi Drug Proven to Cut Cardiovascular Death - How Alnylam's Quarterly TTR-Silencing Injection Treats ATTR Amyloidosis and What HELIOS-B Showed (August 19, 2026)", "description": "Most gene-silencing drugs move a lab value. Vutrisiran moved mortality. Alnylam's quarterly subcutaneous injection silences the TTR gene in the liver to treat ATTR amyloidosis, and in the HELIOS-B trial it became the first RNAi therapeutic proven to reduce cardiovascular death and events in ATTR cardiomyopathy. Here is how it works, from GalNAc chemistry to the heart data that earned its 2025 label.", "datePublished": "2026-08-19", "dateModified": "2026-08-19", "author": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "publisher": { "@type": "Organization", "name": "PepTracker Pro", "logo": { "@type": "ImageObject", "url": "https://peptrackerpro.com/favicon.png" } }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://peptrackerpro.com/blog/vutrisiran-amvuttra-alnylam-ttr-transthyretin-galnac-sirna-rnai-attr-amyloidosis-cardiomyopathy-attr-cm-helios-a-helios-b-cardiovascular-outcomes-quarterly-august-19-2026" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://peptrackerpro.com/blog" }, { "@type": "ListItem", "position": 3, "name": "Vutrisiran (Amvuttra): The First RNAi Drug Proven to Cut Cardiovascular Death - How Alnylam's Quarterly TTR-Silencing Injection Treats ATTR Amyloidosis and What HELIOS-B Showed (August 19, 2026)", "item": "https://peptrackerpro.com/blog/vutrisiran-amvuttra-alnylam-ttr-transthyretin-galnac-sirna-rnai-attr-amyloidosis-cardiomyopathy-attr-cm-helios-a-helios-b-cardiovascular-outcomes-quarterly-august-19-2026" } ] } ] ```